CN116421713A - Anti-aging composition and application thereof - Google Patents
Anti-aging composition and application thereof Download PDFInfo
- Publication number
- CN116421713A CN116421713A CN202310257672.XA CN202310257672A CN116421713A CN 116421713 A CN116421713 A CN 116421713A CN 202310257672 A CN202310257672 A CN 202310257672A CN 116421713 A CN116421713 A CN 116421713A
- Authority
- CN
- China
- Prior art keywords
- aging
- superoxide dismutase
- trimethoxybenzoyl
- fluorobenzyl
- methyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 46
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 46
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims abstract description 27
- -1 3, 4, 5-trimethoxybenzoyl Chemical group 0.000 claims abstract description 25
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 230000036542 oxidative stress Effects 0.000 claims abstract description 13
- 230000035882 stress Effects 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 17
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 13
- 235000005822 corn Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 3
- 239000012507 Sephadex™ Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000003505 heat denaturation Methods 0.000 claims description 2
- 241000209149 Zea Species 0.000 claims 2
- 230000032683 aging Effects 0.000 abstract description 53
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 230000005779 cell damage Effects 0.000 abstract description 4
- 208000037887 cell injury Diseases 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 80
- 230000000694 effects Effects 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102000005936 beta-Galactosidase Human genes 0.000 description 14
- 108010005774 beta-Galactosidase Proteins 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 13
- 240000008042 Zea mays Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 10
- 108010041191 Sirtuin 1 Proteins 0.000 description 10
- 230000032677 cell aging Effects 0.000 description 10
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 10
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 9
- 208000003643 Callosities Diseases 0.000 description 9
- 206010020649 Hyperkeratosis Diseases 0.000 description 9
- 108091007960 PI3Ks Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 7
- 210000005003 heart tissue Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 101150046266 foxo gene Proteins 0.000 description 6
- 239000012669 liquid formulation Substances 0.000 description 6
- 230000009758 senescence Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 4
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 4
- 240000004922 Vigna radiata Species 0.000 description 4
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 4
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AMPHKYRLSOPVBX-YFKPBYRVSA-N allylcysteine Chemical class OC(=O)[C@H](CS)NCC=C AMPHKYRLSOPVBX-YFKPBYRVSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an anti-aging composition and application thereof, and belongs to the technical field of biological medicines. The anti-aging composition of the invention comprises the following components: superoxide dismutase, nicotinamide mononucleotide and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester. The anti-aging composition can remarkably improve the antioxidation capability of aging cells, relieve cell injury caused by oxidative stress and restore the vitality of the aging cells by combining superoxide dismutase, nicotinamide mononucleotide and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester, can be applied to preparation of anti-aging drugs or health care products, and can also be applied to preparation of anti-oxidative stress drugs.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to an anti-aging composition and application thereof.
Background
The average life span of human beings has been gradually increased in the past century, and for this purpose, the prolonged life span is accompanied by the occurrence of a plurality of related diseases, so that the social development is gradually limited and the life of people is influenced, and the related research on aging is particularly important, and the research on aging and most of age-related diseases are found to be mediated by oxidative stress. Aging is a process that changes dynamically over time and is characterized by a gradual accumulation of cellular damage, a decline in functionality, and an increased susceptibility to disease. Currently, the aging process is thought to originate from several fundamental molecular changes, four of which are genomic instability, telomere abrasion, epigenetic changes, and loss of protein homeostasis, respectively. It has been investigated that these characteristics leading to the aging process may be caused by oxidative damage. For example, telomeres are highly susceptible to oxidative damage and are less able to repair than other parts of the chromosome. Thus, oxidative damage may lead to wear of telomeres, accelerate aging and increase the risk of age-related diseases.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide an anti-aging composition for promoting the viability of aging myocardial cells and application thereof.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
in a first aspect, the present invention provides an anti-aging composition comprising the following components: superoxide dismutase, nicotinamide mononucleotide and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester; the mass ratio of the superoxide dismutase to the nicotinamide mononucleotide to the S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester is that the superoxide dismutase: nicotinamide mononucleotide: s- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester=10 (3.334219-33.4219): 0.0131244.
according to the invention, superoxide dismutase, nicotinamide mononucleotide and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester are selected for matching, and the obtained anti-aging composition has the effect of promoting the viability of aging myocardial cells.
Superoxide dismutase (SOD) can catalyze superoxide anions to perform disproportionation reaction to eliminate O 2- The degree of oxidative stress of the organism is reduced, and the antioxidation effect is achieved; nicotinamide Mononucleotide (NMN) is Nicotinamide Adenine Dinucleotide (NAD) in mammals + ) The intermediate of the salvage synthesis way has the effects of resisting oxidation and aging, repairing brain functions, improving insulin resistance and promoting heart injury repair; s- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester (MTC) is a combined derivative of allyl cysteine and gallic acid, and has the effects of protecting nerves and resisting inflammation. The invention combines SOD and NMN with antioxidant effect and MTC with anti-inflammatory effect, plays a role of synergistic interaction, and the obtained anti-aging composition has better antioxidant effect and can restore the activity of aging cells.
As a preferred embodiment of the anti-aging composition of the present invention, the mass ratio of the superoxide dismutase, nicotinamide mononucleotide and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester is superoxide dismutase: nicotinamide mononucleotide: s- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester = 10:33.4219:0.0131244. in the preferable proportion range, the anti-aging composition obtained by combining SOD, NMN and MTC has better anti-oxidation effect and more remarkable anti-aging effect.
As a preferred embodiment of the anti-aging composition of the present invention, the superoxide dismutase is extracted from germinated corns as a raw material. The SOD enzyme activity and purity obtained by extracting germinated corns as raw materials are high, and the antioxidant and anti-aging effects of the anti-aging composition can be further improved.
As a preferred embodiment of the anti-aging composition of the present invention, the extraction of superoxide dismutase comprises the steps of:
(1) Grinding germinated corn with water, leaching, and filtering to obtain crude enzyme solution;
(2) Performing heat denaturation treatment on the crude enzyme solution obtained in the step (1), centrifuging, and retaining supernatant;
(3) Adding acetone into the supernatant obtained in the step (2) for precipitation, centrifuging, and reserving the supernatant;
(4) Purifying the supernatant obtained in the step (3) by cellulose column chromatography, taking distilled water as eluent, and collecting effluent liquid with absorption peak at 280 nm;
(5) Concentrating the effluent of the step (4), purifying by sephadex column chromatography, taking distilled water as eluent, collecting the effluent with absorption peak at 280nm, concentrating, and freeze-drying to obtain superoxide dismutase.
The SOD enzyme obtained by extraction through extraction of germinated corns, acetone precipitation, cellulose column chromatography and sephadex column chromatography is high in activity and purity, safe, simple and convenient in method, low in cost and suitable for being applied to large-scale production.
In a second aspect, the invention provides application of the anti-aging composition in preparation of anti-aging drugs or health care products.
In a third aspect, the present invention provides the use of the above anti-aging composition in the preparation of an anti-oxidative stress medicament.
As a preferred embodiment of the use of the anti-aging composition of the present invention, the anti-oxidative stress drug is a drug for treating cardiovascular diseases caused by oxidative stress.
As a preferred embodiment of the use of the anti-aging composition of the present invention, the anti-aging composition can enhance the ability of cells to scavenge free radicals, alleviate the extent of oxidative damage to cells, and maintain homeostasis within cells.
As a preferred embodiment of the use of the anti-aging composition of the present invention, the anti-aging composition can up-regulate expression of SIRT1 and FOXO related genes in myocardial tissues and inhibit NF- κB pathway.
As a preferred embodiment of the use of the anti-aging composition of the present invention, the anti-aging composition activates ERK1/2 pathway, inhibits PI3K pathway and Cyto-C release in mitochondria to protect myocardial cells.
In a fourth aspect, the invention provides the use of a liquid formulation of superoxide dismutase, a liquid formulation of nicotinamide mononucleotide and a liquid formulation of S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester in combination for the preparation of an anti-ageing medicament.
The liquid preparation of the three medicaments can be used together to effectively protect the myocardial cells of the heart tissue of the organism, relieve the aging damage of the myocardial cells and achieve the anti-aging effect.
In a fifth aspect, the invention provides the use of a liquid formulation of superoxide dismutase, a liquid formulation of nicotinamide mononucleotide and a liquid formulation of S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester in combination for the preparation of an anti-oxidative stress medicament.
The combined application of the liquid preparations of the three medicaments can effectively relieve the damage of heart tissues caused by oxidative stress, and plays a role in protecting the heart tissues.
As a preferred embodiment of the application of the present invention, the concentration of superoxide dismutase in the superoxide dismutase liquid preparation is 10mg/L, the concentration of nicotinamide mononucleotide in the nicotinamide mononucleotide liquid preparation is 3.334219-33.4219mg/L, and the concentration of S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester in the S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester liquid preparation is 0.0131244mg/L.
Compared with the prior art, the invention has the beneficial effects that:
(1) According to the anti-aging composition, the superoxide dismutase, the nicotinamide mononucleotide and the S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester are combined, so that the anti-oxidation capability of aging cells can be remarkably improved, the cell damage caused by oxidative stress is relieved, and the activity of the aging cells is recovered.
(2) The anti-aging composition can inhibit Cyto-C from being released into cytoplasm by mitochondria to reduce the level of active oxygen and hydrogen peroxide in cells, regulate SIRT1 expression to inhibit P53 and NF- κB channels to reduce hypersensitivity of the cells caused by oxidative stress, and up-regulate FOXO expression to reduce the level of active oxygen and hydrogen peroxide in the cells to improve the antioxidant capacity of aging cells, relieve cell damage caused by oxidative stress and restore the activity of the aging cells. Meanwhile, the anti-aging composition disclosed by the invention can promote the expression of ERK1/2 signal pathway related proteins P-P44/42 and P44/42 so as to reduce the level of active oxygen and hydrogen peroxide in cells, inhibit the activation of PI3K and reduce the degree of various stress reactions of cells caused by aging. On the basis, the anti-aging composition can be applied to the preparation of anti-aging medicines or health products and also can be applied to the preparation of anti-oxidative stress medicines.
Drawings
FIG. 1 shows the results of calculation of cell viability in the construction of a cell senescence model according to Experimental example 2 of the present invention;
FIG. 2 is the results of the observation of cell morphology after various treatments in Experimental example 2 of the present invention;
FIG. 3 shows the results of calculation of cell viability after various treatments in Experimental example 2 of the present invention;
FIG. 4 shows the results of measuring the active oxygen levels of cells after various treatments in experimental example 3 of the present invention;
FIG. 5 shows the results of measuring the hydrogen peroxide levels of cells after various treatments in experimental example 3 of the present invention;
FIG. 6 shows the results of measurement of the activity of beta-galactosidase in cells treated differently in experimental example 3 of the present invention;
FIG. 7 shows the results of measurement of the levels of PI3K, P/42, P-P44/42 and Cyto-C protein expression in experimental example 4 after various treatments, wherein A is the development result of Western blotting, and B is the analysis result of the optical density obtained by development;
FIG. 8 shows the results of measuring SIRT1, p53, NF-. Kappa. B, foxo, cyto-C gene expression levels in heart tissue of mice treated differently in Experimental example 4 of the present invention.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the following specific examples.
In the experimental example, H9C2 cells are provided by a cell bank of China academy of sciences;
cell viability was determined using a Cell Counting Kit-8 kit, supplied by Shanghai Biyun biotechnology Co., ltd;
the cellular active oxygen level is measured by an active oxygen detection kit and is provided by Shanghai Biyun biotechnology limited company;
the cellular hydrogen peroxide level is determined by a hydrogen peroxide detection kit and is provided by Shanghai Biyun biotechnology limited company;
the activity of the cell beta-galactosidase is measured by adopting a cell aging beta-galactosidase staining kit and is provided by Shanghai Biyun biotechnology company;
the secondary antibodies adopted by the western blotting method are Phospho-p44/42MAPK, p44/42MAPK (Erk 1/2) anti-body, PI3 Kinase p110α anti-body and Cytochrome c Antibody, which are provided by Cell Signaling Technology;
male C57BL/6 mice were supplied by the Experimental animal center at the university of medical science in the south;
other materials, reagents, etc., unless otherwise specified, are commercially available.
Examples 1 to 2 and comparative examples 1 to 3
The composition components of the anti-aging compositions of examples 1 to 2 and comparative examples 1 to 3 are shown in Table 1.
TABLE 1 composition components of the anti-aging compositions of examples 1-2 and comparative examples 1-3
Experimental example 1 determination of SOD enzyme Activity obtained by extraction of different raw materials
SOD is extracted from germinated corn and germinated mung bean.
The method for extracting SOD from germinated corns comprises the following specific steps:
(1) Grinding 20g of germinated corns with 100mL of water, leaching for 1h, and filtering to obtain crude enzyme solution;
(2) Centrifuging the crude enzyme solution obtained in the step (1) in a water bath at 60 ℃ for 15min, at 4 ℃ and 12000r/min for 20min, and reserving supernatant;
(3) Adding 1.5 times of acetone into the supernatant obtained in the step (2), standing at 4 ℃ for 2 hours, centrifuging at 4 ℃ for 20min at 12000r/min, retaining the supernatant, and centrifuging again after precipitating with a small amount of distilled water solution to remove the precipitate;
(4) Purifying 5mL of the supernatant obtained in the step (3) by using a Cellulose-DE-52 column chromatography, taking distilled water as eluent, collecting 3.5mL of eluent at a flow rate of 0.5mL/min for each tube, and reserving effluent liquid with an absorption peak at 280 nm;
(5) Concentrating the effluent of the step (4), taking 2mL of the concentrated effluent, purifying by SephadexG-75 column chromatography, taking distilled water as eluent, collecting 3mL of the eluent at a flow rate of 0.5mL/min, collecting the effluent with an absorption peak at 280nm, concentrating, and freeze-drying to obtain the superoxide dismutase.
The step of extracting SOD from germinated mung beans is the same as that of germinated corns.
The total enzyme activity, total protein content, specific activity, enzyme activity yield, protein yield and purification multiple of the products obtained in each step of the preparation process of SOD from two sources were measured, and the results are shown in Table 2.
TABLE 2 determination of the product index of the SOD extraction process for germinated maize and germinated mung bean
As shown in Table 2, the SOD activity yield obtained by extracting germinated corns is 39.51%, the specific activity is 3345.63U/mg, the purification multiple is 74.42, and the extraction effect is higher than that of germinated mung beans, which indicates that the activity and purity of the SOD obtained by extracting germinated corns are better, and the SOD obtained by extracting germinated corns is selected as a component of the anti-aging composition. In addition, the SOD extraction method is simple and convenient, has low cost and can be suitable for mass production.
Experimental example 2 Effect of anti-aging composition on aging cell viability
(1) Establishment of cell aging model
The mouse cardiomyocyte H9C2 cell strain is selected as an experimental object, and a cobalt chloride solution is used as a reagent for inducing cell senescence to establish a cell senescence model. The culture condition of H9C2 is 5% CO 2 The culture solution is at 37 DEG CThe DMEM medium containing 10% FBS and 2% penicillin-streptomycin double-antibody solution is replaced with fresh culture medium every 2-3 days, and the fresh culture medium is passaged for 3-4 days, and cells in logarithmic growth phase are taken for experiments, and the subsequent H9C2 cell culture conditions are consistent with the conditions unless specified.
The experiment was set with 6 treatment groups, blank, control, and 4 experimental groups, respectively. Wherein, the blank group is pure culture solution without inoculating cells; the concentration of cobalt chloride in the control group was 0; the concentrations of cobalt chloride in the 4 experimental groups were 1, 2, 4, 8mM, respectively.
H9C2 cells were inoculated into 96-well cell culture plates at 5000 cells/well, after 24 hours of culture, the culture solution was removed, and according to the different treatment groups, the culture solution or cobalt chloride solution was added, after 8 hours of culture, the cell viability was measured and calculated according to the kit instructions, and the results are shown in FIG. 1. The cell viability was calculated as follows:
cell viability = (experiment Kong Xiguang value-blank Kong Xiguang value)/(control Kong Xiguang value-blank Kong Xiguang value) ×100%
As shown in FIG. 1, the survival rate of H9C2 cells treated for 8 hours was nearly 50% when the concentration of cobalt chloride was 2mM, compared with the control group (0 mM cobalt chloride), and thus the cell senescence model was subsequently constructed using 2mM cobalt chloride.
(2) Effect of anti-aging compositions on aging H9C2 cells
The experiment was set up with 7 treatment groups, blank, aged and 5 dosing groups, respectively. Wherein, the blank group is not added with cobalt chloride, the aging group and 5 administration groups are respectively added with 2mM cobalt chloride, and the administration groups are respectively added with the anti-aging compositions of examples 1-2 and comparative examples 1-3.
H9C2 cells were grown at 1X 10 6 Inoculating each/hole into a 6-hole cell culture plate, culturing for 24 hours, removing culture solution, adding culture solution or 2mM cobalt chloride according to different treatment groups respectively, culturing for 8 hours, adding anti-aging compositions of examples 1-2 and comparative examples 1-3 respectively to the dosing groups, adding equivalent culture solution to the blank control group and the aging group, culturing for 24 hours, observing cell morphology and measuring cell survival rate, and testing cell survival rate by using a cell aging model of experiment "(1)The cell morphology is shown in FIG. 2 and the cell viability is shown in FIG. 3.
As shown in fig. 2, the aging group not only decreased the cell number but also distorted and broken the cell morphology compared to the blank group, indicating that the modeling of the cell aging model was successful.
As shown in fig. 2 to 3, the cell viability of the administration groups of examples 1 to 2 and comparative examples 1 to 3 was significantly higher than that of the aging group and the normal morphology of the administration group, but the cell viability was not recovered to the level of the blank group, compared with the aging group, which indicates that the anti-aging compositions of examples 1 to 2 and comparative examples 1 to 3 recovered the cell activity, improved the cell viability, and achieved the effect of alleviating and resisting cell aging. Examples 1-2 showed a more significant increase in the survival of senescent H9C2 cells (P < 0.0001) treated with the anti-aging compositions of examples 1-2 as compared to the anti-aging compositions of comparative examples 1-3, indicating that the anti-aging compositions of the invention were able to further restore cell activity and increase cell survival.
Experimental example 3 Effect of anti-aging composition on aging cell active oxygen and beta-galactosidase
To explore the mechanism of anti-aging compositions, this experiment measured Reactive Oxygen Species (ROS) and hydrogen peroxide (H 2 O 2 ) Level, beta-galactosidase activity.
In this experiment, senescent cells were prepared according to the method of experimental example 2, and 7 treatment groups were set up in total, and the treatment groups were the same as those of experimental example 2 "(2) effect of the anti-aging composition on senescent H9C2 cells", and will not be described in detail here.
(1) Cell ROS, H 2 O 2 Level determination
The method of culturing H9C2 cells in each treatment group was the same as the method of "(2) effect of the anti-aging composition on aging H9C2 cells" in experimental example 2. The cultured cells are used for measuring the ROS and H in the cells according to the instruction of the kit 2 O 2 The level, ROS level measurement is shown in FIG. 4, H 2 O 2 The results of the level measurement are shown in FIG. 5.
As shown in FIG. 4, the H9C2 cells of the aging group generate a large amount of active oxygen compared with the blank control group, which indicates that the aging cell model constructed by the invention causes apoptosis through oxidative stress injury, while the active oxygen level of the aged H9C2 cells is reduced after the aging compositions of examples 1-2 and comparative examples 1-3 are treated, which indicates that the aging compositions of examples 1-2 and comparative examples 1-3 can effectively reduce the active oxygen level in the cells, avoid oxidative stress injury of the cells caused by active oxygen burst, and thus relieve the aging degree of the cells. The aging compositions of examples 1-2 showed more remarkable effect of inhibiting cellular ROS burst than the aging compositions of comparative examples 1-3, which indicates that the anti-aging composition of the invention has better effects of inhibiting cellular ROS burst, reducing cellular ROS level, and alleviating cellular aging.
As shown in FIG. 5, the anti-aging compositions of examples 1 to 2 and comparative examples 1 to 3 each reduced H of H9C2 cells of aging cells compared to the aging group 2 O 2 Level, and H of example 1 2 O 2 The level is close to that of a blank control group, which indicates that the anti-aging composition of the invention can reduce H 2 O 2 The level is consistent with the result of the anti-aging composition for reducing the ROS level of aging cells, and further proves that the anti-aging composition can relieve cell aging by inhibiting oxidative stress of cells, so that the anti-aging effect is achieved.
(2) Determination of cellular beta-galactosidase Activity
The method of culturing H9C2 cells in each treatment group was the same as the method of "(2) effect of the anti-aging composition on aging H9C2 cells" in experimental example 2. The cultured cells were stained with β -galactosidase according to the instructions, and the number of β -galactosidase-positive cells was observed and recorded under a normal light microscope, and the results are shown in fig. 6.
It has been found that the positive rate of beta-galactosidase staining in skin tissue sections of elderly individuals is significantly higher than in skin tissue sections of young individuals, and therefore beta-galactosidase is considered to be one of the biological markers of aging in the study of individuals. As shown in fig. 6, β -galactosidase was stronger in H9C2 cells of the aging group compared to the blank group, indicating that the aging model can result in an enhancement of the activity of β -galactosidase, one of the cellular aging markers. The anti-aging compositions of examples 1-2 and comparative examples 1-3 showed a significant decrease in β -galactosidase activity in H9C2 cells treated with the anti-aging composition, indicating that the anti-aging composition was able to significantly reduce cellular aging, and the β -galactosidase activity of the anti-aging composition of examples was closer to that of the blank control, indicating that the anti-aging composition of the invention had better anti-aging effect.
Experimental example 4 investigation of the cell aging mechanism of the aging-resistant composition
In order to explore the action mechanism of the anti-aging composition, the experiment determines the expression levels of PI3K, P/42, P-P44/42 and Cyto-C proteins of aging cells by Western Blot (WB); SIRT1, p53, NF- κ B, foxo, cyto-C gene expression levels in animal heart tissue were determined by real-time fluorescent quantitative PCR (qRT-PCR).
(1) WB assay of protein expression levels associated with senescent cells
In this experiment, aging cells were prepared in the same manner as in experiment example 2, and 6 treatment groups were set up, which were similar to the treatment group of "(2) effect of the aging-resistant composition on aging H9C2 cells" in experiment example 2, except that the administration group of the aging-resistant composition of example 2 was deleted, and the culture method of H9C2 cells was the same. After washing the cultured cells with pre-chilled PBS, centrifuging at 1500rpm for 10min at 4 ℃, removing the supernatant, adding 70 μl of lysate to lyse the cells, rapidly shaking at 4 ℃ for 30min, and centrifuging at 13200rpm at 4 ℃ for 10min, wherein the obtained supernatants are protein samples of different treatment groups, respectively. Taking 5 μl of protein sample for BCA kit quantification, mixing the remaining protein sample with 4× SDS loading buffer to prepare 1× SDS loading buffer containing protein sample, and heating at 100deg.C for 5min to obtain diluted protein sample. The diluted protein samples were subjected to WB at a protein amount of 10. Mu.g per well, and the protein expression levels of PI3K, P/42, P-P44/42 and Cyto-C were determined, developed using substrate luminescence ECL, and analyzed in an imaging system, and the results are shown in FIG. 7.
As shown in FIG. 7, the anti-aging compositions of example 1 and comparative examples 1 to 3 all promote the expression of ERK1/2 signaling pathway related proteins P-P44/42 and inhibit the expression of PI3K and Cyto-C proteins, compared with the aging group, indicating that the anti-aging composition has the effects of promoting the activation of ERK1/2 cells, inhibiting the activation of PI3K, and inhibiting the release of Cyto-C in mitochondria to cytoplasm, so as to achieve anti-aging effect. In addition, examples 1-2 have better inhibition effect on the expression of PI3K and Cyto-C proteins than the anti-aging compositions of comparative examples 1-3, which indicates that the anti-aging composition of the present application can further inhibit the activation of PI3K and the release of Cyto-C in mitochondria to cytoplasm, thereby enhancing the anti-aging effect.
(2) qRT-PCR determination of related gene expression level of animal heart tissue
In the experiment, male C57BL/6 mice are used as experimental materials, and 5 treatment groups are arranged, namely a blank control group, an aging group and 3 administration groups. Wherein, the blank control group is injected with physiological saline with the same dosage as the aging group and the administration group; the aging group and the administration group were respectively injected with 12.5mL/kg of D-galactose; the anti-aging compositions of example 1, comparative example 1 and comparative example 3 were respectively injected into the administration route, wherein the SOD concentration in the anti-aging composition was 10mg/L, the NMN concentration was 3.334219mg/L, and the MTC concentration was 0.0131244mg/L.
Mice were injected intraperitoneally, once a day, for five consecutive days, according to the treatment group setup. Mice were sacrificed, heart tissue was extracted for RNA and reverse transcribed to cDNA according to kit instructions, qRT-PCR was performed using cDNA as template, selection 2 -ΔΔCt The relative expression levels of SIRT1, p53 and NF- κ B, foxo, cyto-C genes were calculated and the results are shown in FIG. 8.
As shown in FIG. 8, the anti-aging compositions of example 1, comparative example 1 and comparative example 3 each were able to increase the relative expression levels of SIRT1 and foxo genes and decrease the relative expression levels of p53 and NF- κB genes, as compared to the aging group. SIRT1 can deacetylate certain key proteins and thus directly or indirectly participate in the regulation of related signal pathways, for example, SIRT1 deacetylation of p53 can inhibit cell DNA damage and stress-mediated cell senescence, so that the effect of delaying cell senescence is achieved, and at the same time, SIRT1 has an inhibitory effect on NF- κb pathway, and the effects are the same as the experimental results of the invention. The over-expression of foxo is closely related to the anti-aging effect of organisms, and the anti-aging composition can obviously improve the expression of foxo genes, so that the anti-aging composition has better anti-aging effect. In summary, the anti-aging composition of the invention protects myocardial cells by inhibiting the release of Cyto-C from mitochondria into cytoplasm, regulating and controlling the expression of SIRT1 to inhibit P53, NF- κB pathway and up-regulating FOXO expression, thus relieving aging injury, and therefore, the anti-aging composition of the invention can be applied to the preparation of anti-aging drugs or health care products or the preparation of anti-oxidative stress drugs, in particular to the preparation of drugs for treating cardiovascular diseases caused by oxidative stress.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. An anti-aging composition comprising the following components: superoxide dismutase, nicotinamide mononucleotide and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester; the mass ratio of the superoxide dismutase to the nicotinamide mononucleotide to the S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester is that the superoxide dismutase: nicotinamide mononucleotide: s- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester=10 (3.334219-33.4219): 0.0131244.
2. the anti-aging composition of claim 1, wherein the mass ratio of superoxide dismutase, nicotinamide mononucleotide, and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester is superoxide dismutase: nicotinamide mononucleotide: s- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester = 10:33.4219:0.0131244.
3. the anti-aging composition according to claim 1, wherein the superoxide dismutase is extracted from germinated corn.
4. The anti-aging composition of claim 3, wherein the extraction of superoxide dismutase comprises the steps of:
(1) Grinding germinated corn with water, leaching, and filtering to obtain crude enzyme solution;
(2) Performing heat denaturation treatment on the crude enzyme solution obtained in the step (1), centrifuging, and retaining supernatant;
(3) Adding acetone into the supernatant obtained in the step (2) for precipitation, centrifuging, and reserving the supernatant;
(4) Purifying the supernatant obtained in the step (3) by cellulose column chromatography, taking distilled water as eluent, and collecting effluent liquid with absorption peak at 280 nm;
(5) Concentrating the effluent of the step (4), purifying by sephadex column chromatography, taking distilled water as eluent, collecting the effluent with absorption peak at 280nm, concentrating, and freeze-drying to obtain superoxide dismutase.
5. The use of the anti-aging composition of claim 1 in the preparation of anti-aging drugs or health products.
6. Use of the anti-aging composition according to claim 1 for the preparation of an anti-oxidative stress medicament.
7. The use according to claim 6, wherein the anti-oxidative stress medicament is a medicament for the treatment of cardiovascular diseases caused by oxidative stress.
8. The application of superoxide dismutase liquid preparation, nicotinamide mononucleotide liquid preparation and S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester liquid preparation in preparation of anti-aging medicines is provided.
9. The application of the superoxide dismutase liquid preparation, the nicotinamide mononucleotide liquid preparation and the S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester liquid preparation in the preparation of the antioxidant stress medicine is combined.
10. The use according to claim 8 or 9, wherein the superoxide dismutase concentration in the liquid preparation of superoxide dismutase is 10mg/L, the nicotinamide mononucleotide concentration in the liquid preparation of nicotinamide mononucleotide is 3.334219-33.4219mg/L, and the S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester concentration in the liquid preparation of S- (4-fluorobenzyl) -N- (3, 4, 5-trimethoxybenzoyl) -L-cysteine methyl ester is 0.0131244mg/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310257672.XA CN116421713A (en) | 2023-03-16 | 2023-03-16 | Anti-aging composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310257672.XA CN116421713A (en) | 2023-03-16 | 2023-03-16 | Anti-aging composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116421713A true CN116421713A (en) | 2023-07-14 |
Family
ID=87078707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310257672.XA Pending CN116421713A (en) | 2023-03-16 | 2023-03-16 | Anti-aging composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421713A (en) |
-
2023
- 2023-03-16 CN CN202310257672.XA patent/CN116421713A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101047644B1 (en) | External skin composition containing pogongyoung, horse riding, powder or extract extract | |
| CN108685808B (en) | Use of orchid callus extract for preparing skin care composition | |
| CN111012700B (en) | Yam bean fermentation product and application thereof in preparing composition for improving gene expression amount and reducing skin melanin content | |
| TWI757586B (en) | Plant ferment, preparation method thereof and use thereof for liver health care | |
| CN111973647A (en) | Preparation method of honeysuckle flower fermentation product and application of honeysuckle flower fermentation product in improving skin appearance and resisting aging | |
| WO2021060654A1 (en) | Staphylococcus epidermidis strain st-6 and use thereof for improving condition of skin | |
| KR20170129281A (en) | Platelet-derived growth factor-bb production promoter, and mesenchymal stem cell production accelerator, stem cell stabilizer and dermal regenerator comprising the same | |
| CN112451539A (en) | Application of turnip neutral polysaccharide in preparation of antioxidant drugs | |
| KR102233385B1 (en) | Staphylococcus capitis ST-1 strain and skin condition improving uses of thereof | |
| CN116421713A (en) | Anti-aging composition and application thereof | |
| KR20100031839A (en) | Skin external composition containing tussilago farfara and hibiscus mutabilis flower extract | |
| Putri et al. | Clitorea ternatea flower extract induces platelet-derived growth factor (PDGF) and GPx gene overexpression in ultraviolet (UV) B irradiation-induced collagen loss | |
| KR20210037293A (en) | Staphylococcus gallinarum ST-4 strain and skin condition improving uses of thereof | |
| EP2796453B1 (en) | Hydroxymethylfurfural derivative | |
| KR102475936B1 (en) | A cosmetic composition comprising yeast expressing peptide LL-37 | |
| KR102199063B1 (en) | Staphylococcus haemolyticus ST-8 strain and skin condition improving uses of thereof | |
| CN117377480A (en) | Application of nicotinamide mononucleotide and lactobacillus fermentum in preparation of preparation for relieving skin photoaging | |
| KR20070067364A (en) | Composition for promoting the production of hyaluronic acid | |
| KR101893339B1 (en) | Composition comprising GDF11 and uses thereof | |
| Xiuying et al. | Deferring senile effect of polysaccharides from Angelica and Astragalus on aging mice | |
| CN114831312B (en) | Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof | |
| AU2021105462A4 (en) | Use of fructus corni nano-powder in resisting type 2 diabetes mellitus | |
| CN114558061B (en) | Loquat leaf extract and preparation method and application thereof | |
| KR102505332B1 (en) | Cosmetic composition containing extracts of Sophora flavescens, Salvia miltiorrhiza, Scrophularia buergeriana and Acanthopanax Senticosus | |
| TWI716940B (en) | Prevention and/or treatment of psoriasis with 2,4-dimethoxy-6-methylbenzene-1,3-diol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |